Option Chain

Celcuity Inc

CELCNASDAQ · USD

64.37USD0.00 (+0.32%)

135

Celcuity Inc (CELC) Option Chain

Celcuity Inc trades at $64.37, up 0.32%, with an IV Rank of 71.23%. This is high versus the past year, and the company carries a market cap of $3,162M in the Biotechnology industry. On the Nov 20, 2026 chain, the at the money $65.00 strike shows calls at $1.35 / $4.40 and puts at $1.45 / $4.90, both carrying about $2.71 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $65.00 calls, at 49 contracts, and the $60.00 puts, at 3, as of Nov 13, 2026.

Tracking the CELC option chain helps you see every strike and expiry on Celcuity Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of CELC options activity at a glance. Use our scanner to monitor the CELC option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For CELC stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where CELC options are being actively traded, and where they are not.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer.

CALLs									PUTs
Prob. OTM %	Open Interest	Volume	Extrinsic Value	Intrinsic Value	Bid	Ask	Strike	Moneyness %	Bid	Ask	Intrinsic Value	Extrinsic Value	Volume	Open Interest	Prob. OTM %
7.24	33	0	0.33	9.37	7.70	11.70	55.00	-14.56	0.10	1.00	0.00	0.55	0	109	92.76
26.54	240	0	0.98	4.37	3.40	7.30	60.00	-6.79	—	2.60	0.00	2.60	3	49	73.46
55.49	263	49	2.88	0.00	1.35	4.40	65.00	+0.98	1.45	4.90	0.63	2.55	0	133	44.51
80.13	232	7	0.98	0.00	0.20	1.75	70.00	+8.75	4.40	8.30	5.63	0.72	2	271	19.87
93.39	322	0	1.30	0.00	—	1.30	75.00	+16.51	8.60	12.70	10.63	0.02	0	372	6.61

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

IndustryBiotechnology
SectorHealthcare
IV Rank71.23% High
Market cap (M$)3,162
52 weeks high-57.38%
52 weeks low20.23%
Analyst recommendationStrong Buy
1.00
Target price$150.85
134.35% above the current stock price
Dividend—
Payout ratio—
Earnings date2026-11-05
P/E—
Future P/E—
EPS (ttm)-4.71
EPS growth next 5 years—

As of Nov 13, 2026

Browse all Option Chain tickers